TBIO - קפיטליזציית שוק Telesis Bio, Inc.

Telesis Bio, Inc. (TBIO) is a pioneer in benchtop biomaterial synthesis that developed the unique BioXp system for rapid gene printing, accelerating medical research and development. This chart reflects an asset value of 0.01, while a capital shortfall complicates the struggle for market share against equipment manufacturing behemoths. The company's revenue is based on the sale of automated RNA and DNA synthesis systems to pharmaceutical giants and research centers.

Professional capital evaluates the issuer's profile through the lens of its market capitalization. This indicator captures the total value of all shares at the closing price, determining the scale of the business and its liquidity. By analyzing the aggregate value of the company's shares, an investor can see the amplitude of the asset's valuation fluctuations. For Telesis Bio, Inc. (TBIO), volatility is amplified due to export restrictions on DNA synthesis technologies, rendering the asset high-risk amid geopolitical fragmentation.